The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010Development of In-vivo Models of Prion-like Transfer of Alpha-synuclein
Promising Outcomes of Original Grant:
We aimed at assessing the prion-like hypothesis of alpha-synuclein spread. Prions are small proteins that can move between cells, acting as infectious agents... -
MJFF Research Grant, 2010In-vivo SPECT Imaging of Synuclein Aggregation with Morphology Specific Antibody Based Ligands
Promising Outcomes of Original Grant:
The protein alpha-synuclein (a-syn) has been strongly correlated with PD, and small a-syn aggregates are very toxic and may be an early indicator of the disease... -
Rapid Response Innovation Awards, 2010In Vivo Assessment of Alpha-Synuclein Secretion
Objective/Rationale:
Recent data from our lab (Emmanouilidou et al, 2010) suggest that cell-produced physiologically secreted alpha-synuclein can cause the death of neuronal recipient cells. Although... -
Therapeutics Development Initiative, 2010Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's Disease
Promising Outcomes of Original Grant:
We are investigating a regulatory enzyme (type-7 cyclic nucleotide phosphodiesterase, PDE7) as a novel therapeutic target for the treatment of Parkinson’s disease... -
MJFF Research Grant, 2010Regulated rAAV-GDNF to treat Parkinson's disease: Translational research plan
Objective/Rationale:
We are attempting to perfect gene therapy using glial cell line-derived neurotrophic factor (GDNF) for Parkinson’s disease. One part of developing this gene therapy is... -
Neurotrophic Factor Therapies for Parkinson's Disease, 2010CDNF (Cerebral Dopamine Neurotrophic Factor) for Therapy of Parkinson's Disease
Objective/Rationale:
CDNF protein is expressed in human brain, acts differently from known neurotrophic factors and can protect and repair dopamine neurons in two pre-clinical models of Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.